The global injectable benzodiazepines market is expected to experience steady growth, with a projected CAGR of 2.7% in 2020 and beyond, driven by an increasing prevalence of mental health disorders. As injectable benzodiazepines are widely used as the first line of treatment for conditions such as depression, bipolar disorder, schizophrenia, and anxiety, the growing recognition of these conditions worldwide is contributing to the demand for these drugs. The rising adoption of generic injectable benzodiazepines is expected to be a key growth driver, making these treatments more accessible to a broader patient population.
Mental disorders are a significant global concern, with organizations like the World Health Organization (WHO), the European Brain Council (EBC), and the European College of Neuropsychopharmacology (ECNP) reporting that approximately 25% of the global population will experience a mental disorder in their lifetime. In the U.S., 46.6 million adults were reported to suffer from mental disorders in 2017, and these figures are expected to continue rising. The U.S. market is forecasted to hold the largest share of the injectable benzodiazepines market due to this high prevalence of mental health issues.
The COVID-19 pandemic has further amplified the demand for injectable benzodiazepines, as the widespread increase in anxiety levels and mental health challenges among the general population has led to an uptick in the use of these medications. Short-acting injectable benzodiazepines, known for their quick onset of action, are particularly gaining traction in this context. The short-term surge in demand during the pandemic could see continued growth as healthcare systems address both the immediate and long-term mental health impact of the crisis.
In addition to North America, regions like Europe and Asia-Pacific are also witnessing significant trends in mental health. In 2017, 35-40% of people in the EU were affected by mental disorders, with chronic depression contributing to high absenteeism and reduced workplace productivity. Similarly, in India, the prevalence of mental health disorders has been steadily rising, with the country accounting for nearly 15% of the global burden of neurological, mental, and substance abuse disorders. Asia-Pacific as a whole is expected to witness the highest growth rate for injectable benzodiazepines, driven by these increasing mental health challenges.
Key Takeaways:
- The global injectable benzodiazepines market is expected to grow at a CAGR of 2.7% due to rising mental health disorders and the growing adoption of generic injectable drugs.
- The COVID-19 pandemic has led to a short-term surge in demand as anxiety levels increase among the general population.
- Short-acting injectable benzodiazepines are gaining popularity due to their rapid onset of action.
- The U.S., Europe, and Asia-Pacific regions are poised for significant market growth due to rising mental health concerns.
Leading Players in Injectable Benzodiazepines Market
The injectable benzodiazepines market is in the consolidation phase; with 15+ players involved in extensive research and capacity expansion to maintain a strong foothold in the market.
One such study was conducted in Sweden in Apr 2020 to look into the association between paternal and maternal mental disorders with risk of injuries in the adolescents and children. On the similar grounds, a new study by Boston Medical Center revealed that 1 in 3 people receive medication related to opioid use disorder, that too, within a year of non-fatal overdose of the same. Likewise, studies are being conducted across the globe to look for advantages of injectable benzodiazepines and their application in the broader scenario.
The key players in the injectable benzodiazepines market include:
Americas
- Pfizer Inc.
- Akorn Inc
- Dash Pharmaceuticals LLC
- AdvaCare Pharma
Europe
- Hikma Pharmaceuticals (West-Ward Pharmaceuticals)
- F. Hoffmann-La Roche Ltd
- Hameln pharma ltd
- Teva Pharmaceutical Industries Ltd. (Actavis Pharma, Inc.)
- Accord Healthcare Ltd
Asia Pacific
- Sun Pharmaceutical Industries Limited
- Taj Pharmaceuticals Limited
- Troy Laboratories Pty Ltd
- Intas Pharmaceuticals Limited
- Martin Dow
A Detailed Full Report
Key Segments of Injectable benzodiazepines Market
FMI’s study on the injectable benzodiazepines market offers information divided into three important segments – drug class, indication, time of action, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Drug Class
- Diazepam
- Lorazepam
- Midazolam
Time of Action
- Short Acting
- Long Acting
Indication
- Agitation & Aggression
- Anxiety
- Alcohol Withdrawal
- Muscle Spasm
- Seizures
- Tetanus
- Sedation
- Anaesthesia
- Insomnia
- Status Epilepticus
Distribution Channel
- Hospital
- Ambulatory Surgical centers
- Diagnostics Centers
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube